Persist AI
Persist AI is a biotechnology company pioneering the use of AI-driven robotics to accelerate and transform pharmaceutical formulation development. Their mission is to deliver life-saving drugs faster, with fewer side effects, and improved patient outcomes by leveraging advanced automation, machine learning, and high-throughput experimentation. Persist AI's integrated platform addresses the bottlenecks of traditional drug formulation by combining custom robotics, computational chemistry, and proprietary AI models, enabling rapid, scalable, and cost-effective development of complex drug delivery systems such as long-acting injectables. With a global presence and a team of experts in drug delivery, automation, and machine learning, Persist AI is committed to making advanced drug delivery systems more accessible and efficient for the pharmaceutical industry worldwide. The company also demonstrates a strong commitment to data protection, privacy, and security, implementing robust technical and organizational measures in compliance with international standards.
Industries
Nr. of Employees
small (1-50)
Persist AI
1001 Riverside PKWY., West Sacramento, CA, 95605
Products
AI-driven robotic formulation platform (Cloud Lab platform)
Integrated platform combining custom robotics, integrated analytical instruments, microfluidics, and machine-learning models to perform high-throughput formulation experiments, analyze results, and generate next-step experimental protocols.
AI-driven robotic formulation platform (Cloud Lab platform)
Integrated platform combining custom robotics, integrated analytical instruments, microfluidics, and machine-learning models to perform high-throughput formulation experiments, analyze results, and generate next-step experimental protocols.
Expertise Areas
- Formulation development for long-acting injectables
- High-throughput formulation screening and automation
- AI/ML-driven predictive modeling for formulation and PK
- Microfluidics and miniaturized process development
Key Technologies
- Robotic high-throughput automation
- Machine learning for formulation prediction
- Microfluidics
- HPLC
Key People
Dr. Amjad Basha Mohammad
Head of Advanced Manufacturing
Dr. Ramesh Rachapudi
Vice President of Business Development, Europe and Asia Markets
Dr. Amjad Basha Mohammad
Head of Advanced Manufacturing
Dr. Ramesh Rachapudi
Vice President of Business Development, Europe and Asia Markets
News & Updates
Persist AI secured $12 million in Series A funding to expand their cloud lab platform and deploy a cGMP-compatible manufacturing line, validating their vision to transform drug formulation development.
Persist AI raised $4 million in seed financing, led by 2048 Ventures, to accelerate the development of their AI-driven drug formulation platform.
Persist AI participated in the prestigious Y Combinator accelerator, Winter 2023 batch, furthering their growth and industry connections.
An in-depth article on Persist AI's $12M Series A funding, their mission to transform drug formulation development, and the impact of their AI-driven platform on accelerating drug delivery to patients.
Coverage of Persist AI's $4M seed round, led by 2048 Ventures, highlighting their innovative approach to long-acting injectable formulations and the potential to halve development timelines for chronic disease treatments.
Announcement of a collaboration between Persist AI and Nivagen to co-develop a next-generation manufacturing process for long-acting injectable drugs, leveraging AI-based formulation technology and advanced manufacturing capabilities.
Persist AI secured $12 million in Series A funding to expand their cloud lab platform and deploy a cGMP-compatible manufacturing line, validating their vision to transform drug formulation development.
Persist AI raised $4 million in seed financing, led by 2048 Ventures, to accelerate the development of their AI-driven drug formulation platform.
Persist AI participated in the prestigious Y Combinator accelerator, Winter 2023 batch, furthering their growth and industry connections.
An in-depth article on Persist AI's $12M Series A funding, their mission to transform drug formulation development, and the impact of their AI-driven platform on accelerating drug delivery to patients.
Coverage of Persist AI's $4M seed round, led by 2048 Ventures, highlighting their innovative approach to long-acting injectable formulations and the potential to halve development timelines for chronic disease treatments.
Announcement of a collaboration between Persist AI and Nivagen to co-develop a next-generation manufacturing process for long-acting injectable drugs, leveraging AI-based formulation technology and advanced manufacturing capabilities.